The recent FDA approval of Aphexda combined with filgrastim improved the collection of stem cells in patients with multiple myeloma. Stem cell transplantation is an important treatment method for ...
The FDA has approved the CXCR4 antagonist motixafortide (Aphexda) for use with filgrastim (Neupogen) to mobilize stem cells for autologous transplantation in multiple myeloma, BioLineRx announced on ...
The FDA approved motixafortide combined with filgrastim for mobilization of hematopoietic stem cells into peripheral blood during collection for subsequent autologous transplantation in individuals ...
- APHEXDA is the first innovation in stem cell mobilization for multiple myeloma to be approved in the U.S. in a decade - - One dosage of APHEXDA plus filgrastim enabled a majority of patients to ...
The US Food and Drug Administration (FDA) has approved motixafortide (Aphexda, BioLineRx) in combination with filgrastim (G-CSF) to mobilize hematopoietic stem cells for collection and subsequent ...
Key Highlights Motixafortide effectively mobilized sufficient hematopoietic stem cells (HSCs) in patients with sickle cell disease enabling accelerated access to gene therapies 90% (9 of 10) of ...
Interobserver Variability in the Detection of Cervical-Thoracic Hodgkin's Disease by Computed Tomography PURPOSE: The efficacy of a high- versus a standard-dose filgrastim (recombinant human ...
TEL AVIV, Israel, Sept. 11, 2023 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ/TASE: BLRX), a commercial stage biopharmaceutical company focused on certain cancers and rare diseases, today announced that the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback